United States Rare Respiratory Diseases Biotech Company Avalyn Pharma Nasdaq IPO Share Price Increased +63.8% on Day 1 Trading (30/4/26: IPO Price: $18, Closing $29.49) to $1.2 Billion Market Value & Raised $300 Million in IPO, Founded in 2011 by Mark Surber
2nd May 2026 | Hong Kong
United States rare respiratory diseases biotech company Avalyn Pharma Nasdaq IPO share price increased +63.8% on day 1 trading (30/4/26: IPO Price: $18, Closing $29.49) to $1.2 billion market value, and raised $300 million in the IPO. Avalyn Pharma was founded in 2011 by Mark Surber. Avalyn Pharma – Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (“PPF”). AP01 has demonstrated encouraging tolerability and clinical activity across Phase 1b and an ongoing, multi-year open-label extension trial, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone data. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (“IPF”). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver dual antifibrotic mechanisms through a single lung-targeted platform. By leveraging its proprietary drug-device approach and deep expertise in rare respiratory disease development, Avalyn aims to establish a new standard of care in pulmonary fibrosis through inhaled, lung-targeted therapies.
“ United States Rare Respiratory Diseases Biotech Company Avalyn Pharma Nasdaq IPO Share Price Increased +63.8% on Day 1 Trading (30/4/26: IPO Price: $18, Closing $29.49) to $1.2 Billion Market Value & Raised $300 Million in IPO, Founded in 2011 by Mark Surber “
![](https://www.caproasia.com/wp-content/uploads/2025/08/Air-Charter-Service-728x90-1.png")
United States Rare Respiratory Diseases Biotech Company Avalyn Pharma Nasdaq IPO Share Price Increased +63.8% on Day 1 Trading (30/4/26: IPO Price: $18, Closing $29.49) to $1.2 Billion Market Value & Raised $300 Million in IPO, Founded in 2011 by Mark Surber
Caproasia Users
- Manage $20 million to $30 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2026 Investment Day
- March - Hong Kong
- March - Singapore
- April - Hong Kong
- April - Singapore
- July - Hong Kong
- July - Singapore
- Sept- Hong Kong
- Sept - Singapore
- Oct- Hong Kong
- Nov - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
